ClinicalTrials.govpublic full text
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
endometrial cancer, durvalumab, olaparib, primary advanced endometrial cancer (1l), figo iii or iv, recurrent endometrial cancer (1l), dmmr, pmmr, real-world evidence, patient-reported outcome, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 827738
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.